Opioid Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major opioid use disorder markets reached a value of US$ 2.0 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 4.4 Billion by 2034, exhibiting a growth rate (CAGR) of 7.14% during 2024-2034.
The opioid use disorder market has been comprehensively analyzed in IMARC's new report titled "Opioid Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Opioid use disorder (OUD) is a chronic medical condition that is characterized by the persistent use of opioids. It can have devastating consequences for individuals and their families, such as increased risk of overdose, death, and physical and mental health problems. Some of the common symptoms of OUD are intense cravings for opioids, continued use despite negative consequences, withdrawal symptoms when attempting to quit, tolerance, and difficulty controlling or reducing use. Other signs may include changes in mood, behavior, and physical appearance, as well as social and occupational dysfunction. The diagnosis of opioid use disorder typically involves a comprehensive evaluation by a healthcare professional, including physical exams, laboratory tests, and a review of the patient's medical and substance use history.
The rising prevalence of opioid addiction, including prescription painkillers and illegal drugs like heroin and fentanyl, is primarily augmenting the opioid use disorder market. Apart from this, the widespread adoption of medication-assisted treatment (MAT) for treating opioid use disorder on account of its several associated benefits, such as improved outcomes, reduced risk of relapse, increased likelihood of long-term recovery, etc., is creating a positive outlook for the market. Moreover, numerous government agencies are taking initiatives to address the opioid epidemic by funding addiction treatment programs and introducing regulatory measures to limit opioid prescriptions. This, in turn, is acting as another significant growth-inducing factor. Additionally, the ongoing development of novel treatment options and formulations, including long-acting injectables and implantable devices, that offer longer-lasting relief from opioid withdrawal symptoms and cravings is also bolstering the market growth. Moreover, the increasing utilization of behavioral therapies to help patients identify triggers and develop coping mechanisms to lower the likelihood of relapse is further propelling the market. Besides this, several biotechnological advancements, such as the introduction of opioid vaccines, which assist in reducing the risk of addiction and overdose by preventing opioids from crossing the blood-brain barrier, are expected to drive the opioid use disorder market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the opioid use disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for opioid use disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the opioid use disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the opioid use disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the opioid use disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current opioid use disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the opioid use disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the opioid use disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the opioid use disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of opioid use disorder across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid use disorder by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid use disorder by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with opioid use disorder across the seven major markets?
What is the size of the opioid use disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of opioid use disorder?
What will be the growth rate of patients across the seven major markets?
Opioid Use Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for opioid use disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the opioid use disorder market?
What are the key regulatory events related to the opioid use disorder market?
What is the structure of clinical trial landscape by status related to the opioid use disorder market?
What is the structure of clinical trial landscape by phase related to the opioid use disorder market?
What is the structure of clinical trial landscape by route of administration related to the opioid use disorder market?
The opioid use disorder market has been comprehensively analyzed in IMARC's new report titled "Opioid Use Disorder Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Opioid use disorder (OUD) is a chronic medical condition that is characterized by the persistent use of opioids. It can have devastating consequences for individuals and their families, such as increased risk of overdose, death, and physical and mental health problems. Some of the common symptoms of OUD are intense cravings for opioids, continued use despite negative consequences, withdrawal symptoms when attempting to quit, tolerance, and difficulty controlling or reducing use. Other signs may include changes in mood, behavior, and physical appearance, as well as social and occupational dysfunction. The diagnosis of opioid use disorder typically involves a comprehensive evaluation by a healthcare professional, including physical exams, laboratory tests, and a review of the patient's medical and substance use history.
The rising prevalence of opioid addiction, including prescription painkillers and illegal drugs like heroin and fentanyl, is primarily augmenting the opioid use disorder market. Apart from this, the widespread adoption of medication-assisted treatment (MAT) for treating opioid use disorder on account of its several associated benefits, such as improved outcomes, reduced risk of relapse, increased likelihood of long-term recovery, etc., is creating a positive outlook for the market. Moreover, numerous government agencies are taking initiatives to address the opioid epidemic by funding addiction treatment programs and introducing regulatory measures to limit opioid prescriptions. This, in turn, is acting as another significant growth-inducing factor. Additionally, the ongoing development of novel treatment options and formulations, including long-acting injectables and implantable devices, that offer longer-lasting relief from opioid withdrawal symptoms and cravings is also bolstering the market growth. Moreover, the increasing utilization of behavioral therapies to help patients identify triggers and develop coping mechanisms to lower the likelihood of relapse is further propelling the market. Besides this, several biotechnological advancements, such as the introduction of opioid vaccines, which assist in reducing the risk of addiction and overdose by preventing opioids from crossing the blood-brain barrier, are expected to drive the opioid use disorder market in the coming years.
IMARC Group’s new report provides an exhaustive analysis of the opioid use disorder market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for opioid use disorder and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the opioid use disorder market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the opioid use disorder market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the opioid use disorder market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current opioid use disorder marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the opioid use disorder market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the opioid use disorder market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the opioid use disorder market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (?2018-2034?) of opioid use disorder across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid use disorder by age across the seven major markets?
What is the number of prevalent cases (?2018-2034?) of opioid use disorder by gender across the seven major markets?
How many patients are diagnosed (?2018-2034?) with opioid use disorder across the seven major markets?
What is the size of the opioid use disorder patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of opioid use disorder?
What will be the growth rate of patients across the seven major markets?
Opioid Use Disorder: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for opioid use disorder drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the opioid use disorder market?
What are the key regulatory events related to the opioid use disorder market?
What is the structure of clinical trial landscape by status related to the opioid use disorder market?
What is the structure of clinical trial landscape by phase related to the opioid use disorder market?
What is the structure of clinical trial landscape by route of administration related to the opioid use disorder market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OPIOID USE DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OPIOID USE DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OPIOID USE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OPIOID USE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OPIOID USE DISORDER - UNMET NEEDS
10 OPIOID USE DISORDER - KEY ENDPOINTS OF TREATMENT
11 OPIOID USE DISORDER - MARKETED PRODUCTS
11.1 List of Opioid Use Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Revia (Naltrexone oral)
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Subutex (Buprenorphine extended-release) - Indivior
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vivitrol (Naltrexone controlled-release) - Alkermes
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lucemyra (Lofexidine) - Britannia Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OPIOID USE DISORDER - PIPELINE DRUGS
12.1 List of Opioid Use Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 INDV-2000 - Indivior
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AZD4041 - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 KNX100 - Kinoxis Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 DMX-1002 - ATAI Life Sciences/DemeRx
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MN166 - MediciNova
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OPIOID USE DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OPIOID USE DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OPIOID USE DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Opioid Use Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Opioid Use Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Opioid Use Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Opioid Use Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Opioid Use Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Opioid Use Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Opioid Use Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Opioid Use Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Opioid Use Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Opioid Use Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Opioid Use Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Opioid Use Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Opioid Use Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Opioid Use Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Opioid Use Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Opioid Use Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Opioid Use Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Opioid Use Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Opioid Use Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Opioid Use Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Opioid Use Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Opioid Use Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Opioid Use Disorder - Access and Reimbursement Overview
16 OPIOID USE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OPIOID USE DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OPIOID USE DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 OPIOID USE DISORDER - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 OPIOID USE DISORDER - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 OPIOID USE DISORDER - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 OPIOID USE DISORDER - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 OPIOID USE DISORDER - UNMET NEEDS
10 OPIOID USE DISORDER - KEY ENDPOINTS OF TREATMENT
11 OPIOID USE DISORDER - MARKETED PRODUCTS
11.1 List of Opioid Use Disorder Marketed Drugs Across the Top 7 Markets
11.1.1 Revia (Naltrexone oral)
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
11.1.2 Subutex (Buprenorphine extended-release) - Indivior
11.1.2.1 Drug Overview
11.1.2.2 Mechanism of Action
11.1.2.3 Regulatory Status
11.1.2.4 Clinical Trial Results
11.1.2.5 Sales Across Major Markets
11.1.3 Vivitrol (Naltrexone controlled-release) - Alkermes
11.1.3.1 Drug Overview
11.1.3.2 Mechanism of Action
11.1.3.3 Regulatory Status
11.1.3.4 Clinical Trial Results
11.1.3.5 Sales Across Major Markets
11.1.4 Lucemyra (Lofexidine) - Britannia Pharmaceuticals
11.1.4.1 Drug Overview
11.1.4.2 Mechanism of Action
11.1.4.3 Regulatory Status
11.1.4.4 Clinical Trial Results
11.1.4.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 OPIOID USE DISORDER - PIPELINE DRUGS
12.1 List of Opioid Use Disorder Pipeline Drugs Across the Top 7 Markets
12.1.1 INDV-2000 - Indivior
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AZD4041 - AstraZeneca
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
12.1.3 KNX100 - Kinoxis Therapeutics
12.1.3.1 Drug Overview
12.1.3.2 Mechanism of Action
12.1.3.3 Clinical Trial Results
12.1.3.4 Safety and Efficacy
12.1.3.5 Regulatory Status
12.1.4 DMX-1002 - ATAI Life Sciences/DemeRx
12.1.4.1 Drug Overview
12.1.4.2 Mechanism of Action
12.1.4.3 Clinical Trial Results
12.1.4.4 Safety and Efficacy
12.1.4.5 Regulatory Status
12.1.5 MN166 - MediciNova
12.1.5.1 Drug Overview
12.1.5.2 Mechanism of Action
12.1.5.3 Clinical Trial Results
12.1.5.4 Safety and Efficacy
12.1.5.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. OPIOID USE DISORDER - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. OPIOID USE DISORDER – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 OPIOID USE DISORDER - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Opioid Use Disorder - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Opioid Use Disorder - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Opioid Use Disorder - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Opioid Use Disorder - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Opioid Use Disorder - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Opioid Use Disorder - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Opioid Use Disorder - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Opioid Use Disorder - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Opioid Use Disorder - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Opioid Use Disorder - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Opioid Use Disorder - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Opioid Use Disorder - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Opioid Use Disorder - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Opioid Use Disorder - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Opioid Use Disorder - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Opioid Use Disorder - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Opioid Use Disorder - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Opioid Use Disorder - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Opioid Use Disorder - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Opioid Use Disorder - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Opioid Use Disorder - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Opioid Use Disorder - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Opioid Use Disorder - Access and Reimbursement Overview
16 OPIOID USE DISORDER - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 OPIOID USE DISORDER MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 OPIOID USE DISORDER MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
